NO965342L - PEGyleringsreagenser og forbindelser dannet ved anvendelse av slike - Google Patents

PEGyleringsreagenser og forbindelser dannet ved anvendelse av slike

Info

Publication number
NO965342L
NO965342L NO965342A NO965342A NO965342L NO 965342 L NO965342 L NO 965342L NO 965342 A NO965342 A NO 965342A NO 965342 A NO965342 A NO 965342A NO 965342 L NO965342 L NO 965342L
Authority
NO
Norway
Prior art keywords
biologically active
compounds
compounds formed
peptide polymer
conjugates
Prior art date
Application number
NO965342A
Other languages
English (en)
Other versions
NO965342D0 (no
Inventor
Tadahiko Kohno
Dave Kachensky
Milton Harris
Original Assignee
Amgen Boulder Inc
Shearwater Polymers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc, Shearwater Polymers Inc filed Critical Amgen Boulder Inc
Publication of NO965342D0 publication Critical patent/NO965342D0/no
Publication of NO965342L publication Critical patent/NO965342L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Biologisk aktive konjugater som er dannet ved omsetning av en tiol- komponent av et biologisk aktivt molekyl med en ikke-peptid-polymer med en aktiv sulfonkomponent. Forbindelser med formel Rj-X-Rj, hvori minst én R^ ogRj er et biologisk aktivt molekyl med en reaktiv tiolkomponent som danner en kovalent binding med X, en Michael- akseptoraktivert ikke-peptid-polymer, er også beskrevet. Fremgangsmåte for fremstilling av konjugatene og forbind- elsene, så vel som farmasøytiske preparater inneholdende disse er også beskrevet. Aktiverte polymerer egnede for binding til mange forskjellige molekyler og overflater er også beskrevet .
NO965342A 1994-06-14 1996-12-12 PEGyleringsreagenser og forbindelser dannet ved anvendelse av slike NO965342L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/259,413 US6552170B1 (en) 1990-04-06 1994-06-14 PEGylation reagents and compounds formed therewith
PCT/US1995/007555 WO1995034326A1 (en) 1994-06-14 1995-06-14 Pegylation reagents and compounds formed therewith

Publications (2)

Publication Number Publication Date
NO965342D0 NO965342D0 (no) 1996-12-12
NO965342L true NO965342L (no) 1997-02-14

Family

ID=22984842

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965342A NO965342L (no) 1994-06-14 1996-12-12 PEGyleringsreagenser og forbindelser dannet ved anvendelse av slike

Country Status (15)

Country Link
US (2) US6552170B1 (no)
EP (1) EP0758906A1 (no)
CN (1) CN1158089A (no)
AU (1) AU2828695A (no)
BG (1) BG101095A (no)
BR (1) BR9507999A (no)
CA (1) CA2191971C (no)
CZ (1) CZ357696A3 (no)
EE (1) EE9600182A (no)
FI (1) FI964985A7 (no)
HU (1) HUT77529A (no)
NO (1) NO965342L (no)
PL (1) PL317894A1 (no)
SK (1) SK159596A3 (no)
WO (1) WO1995034326A1 (no)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
SK288144B6 (sk) 1996-02-09 2013-12-02 Amgen, Inc. Pharmaceutical composition and its use for treating inflammatory diseases
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
WO1998024463A2 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
WO1998032466A1 (en) * 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US5912342A (en) * 1997-08-12 1999-06-15 Heinonen; Petri Compounds a containing a solid support
CN1084209C (zh) * 1997-11-07 2002-05-08 复旦大学 一种高分子抗肿瘤导向药物及其制备方法
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
MXPA02003176A (es) * 1999-10-04 2002-09-30 Shearwater Corp Neuropeptidos estabilizados por polimero.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
IL149340A0 (en) 1999-11-18 2002-11-10 Corvas Int Inc Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
FR2835829B1 (fr) * 2002-02-13 2007-09-14 Centre Nat Rech Scient Nouveau procede de preparation de biopuces a adn ou a proteines et leurs applications
WO2003093433A2 (en) * 2002-05-02 2003-11-13 Regents Of The University Of Minnesota Fibrin-based biomatrix
WO2003093296A2 (en) 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
AU2003233119A1 (en) * 2002-05-08 2003-11-11 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
EP1539811A4 (en) * 2002-09-16 2006-05-24 Elusys Therapeutics Inc PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
ES2781475T3 (es) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
MXPA05007151A (es) * 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP4980048B2 (ja) 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
NZ542873A (en) * 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
US7790835B2 (en) 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
JP4646003B2 (ja) * 2004-02-03 2011-03-09 旭化成株式会社 磁気ビーズを用いた被検物質の検出方法
EP2479277B1 (en) 2004-07-22 2015-09-02 Five Prime Therapeutics, Inc. Use of MGD-CSF in a method of treatment of Alzheimer's disease.
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
DE602006017071D1 (de) 2005-01-25 2010-11-04 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8293708B2 (en) * 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
CA2630703C (en) 2005-11-22 2014-05-20 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
US20070179615A1 (en) * 2006-01-31 2007-08-02 Sdgi Holdings, Inc. Intervertebral prosthetic disc
US20070179618A1 (en) * 2006-01-31 2007-08-02 Sdgi Holdings, Inc. Intervertebral prosthetic disc
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
TWI428448B (zh) 2006-03-24 2014-03-01 Syntonix Pharmaceuticals Inc 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５
BRPI0713963A2 (pt) * 2006-07-07 2012-11-27 Novo Nordisk Healthcare Ag conjugados de proteìna e métodos para sua preparação
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
JP5340956B2 (ja) 2006-12-20 2013-11-13 アーケマ・インコーポレイテッド ポリマーの封入および／または結合
US7943728B2 (en) 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8183201B2 (en) 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
US8415453B2 (en) 2007-02-13 2013-04-09 Academia Sinica Lung cancer-targeted peptides and applications thereof
US8088887B2 (en) 2007-02-13 2012-01-03 Academia Sinica Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
TW200911289A (en) 2007-08-09 2009-03-16 Syntonix Pharmaceuticals Inc Immunomodulatory peptides
CA2696699A1 (en) * 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
CN101820920B (zh) * 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
US8541543B2 (en) 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
CA2707979A1 (en) * 2007-12-13 2009-06-18 Biovectra Inc. Polypeptides modified by protein trans-splicing technology
US9134317B2 (en) * 2008-01-18 2015-09-15 Alan Kleinfeld Development and use of cysteine-labeled fluorescent probes of unbound analytes
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
KR20130116386A (ko) 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US20090281054A1 (en) * 2008-05-06 2009-11-12 Venkata Reddy Compositions and methods comprising capuramycin analogues
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
EP2161031A1 (en) * 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
CN102272151B (zh) * 2008-11-04 2014-08-20 詹森药业有限公司 Crhr2肽激动剂及其用途
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
WO2011005540A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
US20110097302A1 (en) * 2009-07-16 2011-04-28 Ta Tung Yuan Il-1ra-polymer conjugates
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
HUE028832T2 (en) * 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
US20110105397A1 (en) * 2009-11-04 2011-05-05 Gengo Peter J Method for treating heart failure with stresscopin-like peptides
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
NZ600544A (en) 2009-12-23 2014-06-27 Univ Nat Cheng Kung Compositions and methods for the treatment of angiogenesis-related eye diseases
CA2786476A1 (en) * 2010-01-14 2011-07-21 Ngm Biopharmaceuticals, Inc. Methods of treating glucose metabolism disorders
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
GB201105584D0 (en) 2011-04-01 2011-05-18 Imp Innovations Ltd Cancer methods
DK2585098T3 (da) 2010-06-28 2014-11-03 Five Prime Therapeutics Inc Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
KR101910779B1 (ko) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Ｆｇｆｒ１ 세포밖 도메인 조합치료
JP6033229B2 (ja) 2010-11-24 2016-11-30 レクシコン ファーマシューティカルズ インコーポレイテッド Ｎｏｔｕｍペクチンアセチルエステラーゼと結合する抗体
AU2012205384B2 (en) 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
KR101883803B1 (ko) 2011-01-20 2018-07-31 프로탈릭스 리미티드 식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
US9140698B2 (en) 2011-04-06 2015-09-22 The Board Of Regents Of The University Of Texas System Modulating bacterial MAM polypeptides in pathogenic disease
AU2012262488A1 (en) 2011-05-31 2014-01-16 Airware, Inc. Re-calibration of AB NDIR gas sensors
PT3513804T (pt) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013026015A1 (en) 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Muc1 ligand traps for use in treating cancers
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
CA2857539C (en) 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
KR101855242B1 (ko) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
HK1214539A1 (zh) 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
US9789156B2 (en) 2013-03-11 2017-10-17 Dana-Farber Cancer Institute, Inc. Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
US20160067307A1 (en) 2013-05-01 2016-03-10 Five Prime Therapeutics, Inc. Methods of treating cancer
SG10201703977UA (en) 2013-05-23 2017-06-29 Five Prime Therapeutics Inc Methods of treating cancer
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
CA2916399C (en) 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
JP7109160B2 (ja) 2014-06-18 2022-07-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
BR112017011530A2 (pt) 2014-12-03 2018-03-13 Proclara Biosciences Inc polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
US11020160B2 (en) 2016-03-21 2021-06-01 Warsaw Orthopedic, Inc. Surgical injection system and method
BR112018070459A2 (pt) 2016-04-04 2019-02-12 Shire Human Genetic Therapies, Inc. inibidor da c1 esterase conjugado e usos do mesmo
US11174321B2 (en) 2016-04-06 2021-11-16 Csl Limited Method of treating atherosclerosis
US10709814B2 (en) 2016-04-22 2020-07-14 Warsaw Orthopedic, Inc. Osteoimplant comprising an insoluble fibrous polymer
ES2981471T3 (es) 2016-04-25 2024-10-09 Five Prime Therapeutics Inc NOPE para el tratamiento de la pérdida de masa muscular y la debilidad muscular patológicas
CA3035561A1 (en) 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
US10294264B2 (en) 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
CA3100071A1 (en) 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IN150740B (no) 1978-11-24 1982-12-04 Hoffmann La Roche
US4760067A (en) * 1979-08-15 1988-07-26 Merck & Co., Inc. Allylsulfoxide enzyme inhibitors
EP0040506B1 (en) 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (ja) 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4966888A (en) 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
US4522750A (en) 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
SE470099B (sv) 1984-05-17 1993-11-08 Jerker Porath Sulfonaktiverade tioeteradsorbenter för separation av t ex protein
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4670563A (en) 1984-06-20 1987-06-02 Sanofi Imidazolides as intermediates for the synthesis of cytotoxic conjugates
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
SE454885B (sv) 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS62185029A (ja) 1986-02-07 1987-08-13 Ajinomoto Co Inc 修飾インタ−ロイキン−２
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IN165717B (no) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4965271A (en) 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5359032A (en) 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
GB2220662A (en) 1987-08-26 1990-01-17 Biogen Inc Biological materials,processes for producing biological materials and for using such materials in therapy
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL90339A (en) 1989-05-18 1996-10-16 Yeda Res & Dev Anti-cytotoxic protein and its purification
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
JPH0240399A (ja) 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
GB8824592D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Purification process
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
WO1990005534A1 (en) 1988-11-23 1990-05-31 Genentech, Inc. Polypeptide derivatives
WO1990006774A1 (en) 1988-12-22 1990-06-28 Xoma Corporation Hindered linking agents and methods
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
EP0386289A1 (en) 1989-03-07 1990-09-12 Taniguchi, Tadatsugu, Dr. Recombinant interleukin-2 receptor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
AU636608B2 (en) 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
EP0502956B1 (en) 1989-11-29 1997-04-23 Amgen Boulder Inc. Production of recombinant human interleukin-1 inhibitor
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
AU649245B2 (en) 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
DK0594772T3 (no) * 1991-07-04 1997-02-24 Immunodex K S
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5569779A (en) * 1991-12-23 1996-10-29 Albemarle Corporation Polyfunctional michael addition products
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0622394A1 (en) 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use
US5958409A (en) 1993-07-30 1999-09-28 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
GB9317618D0 (en) * 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols

Also Published As

Publication number Publication date
SK159596A3 (en) 1997-08-06
FI964985A0 (fi) 1996-12-12
EP0758906A1 (en) 1997-02-26
NO965342D0 (no) 1996-12-12
US20030190304A1 (en) 2003-10-09
HU9603442D0 (en) 1997-02-28
FI964985L (fi) 1996-12-16
CN1158089A (zh) 1997-08-27
FI964985A7 (fi) 1996-12-16
CA2191971A1 (en) 1995-12-21
BR9507999A (pt) 1997-08-12
BG101095A (en) 1997-09-30
CA2191971C (en) 2002-03-05
US6552170B1 (en) 2003-04-22
HUT77529A (hu) 1998-05-28
WO1995034326A1 (en) 1995-12-21
CZ357696A3 (en) 1997-03-12
AU2828695A (en) 1996-01-05
PL317894A1 (en) 1997-04-28
EE9600182A (et) 1998-02-16

Similar Documents

Publication Publication Date Title
NO965342L (no) PEGyleringsreagenser og forbindelser dannet ved anvendelse av slike
Carlier et al. Dimerization of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product
AU5812400A (en) Carrier-drug conjugate
EP0624594A3 (de) Monomere Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
HUT60484A (en) Process for applying acid-splitted connecting molecules for the controlled release of biologically active compounds
PT624377E (pt) Conjugados de farmacos antitumorais clivaveis por enzimas lisossomicas
DE68921982D1 (de) Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
WO1999041273A3 (en) Pna and dna conjugates and methods for preparation thereof
NO992167L (no) Preparater og fremgangsmÕter for immobilisering av nukleinsyrer til faste bµrere
AU542967B2 (en) Preparation of oligonucleotides
JP2005503474A (ja) 構造により特徴付けられている機能をもつ重合体
DK0573848T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
DE69637876D1 (de) Ng und zwischenprodukt dafür
DE60013161D1 (de) Neue fucosylierte oligosaccharide und verfahren zu deren herstellung
DE69032458D1 (de) Ultraviolett absorbierende Linse und Verfahren zu deren Herstellung
FR2630449B1 (fr) Nouveau produit d'addition entre un thiol et un polybutene comportant une double liaison carbone-carbone et procede de preparation
Levesque et al. Protein thioacylation. 1. Reagents design and synthesis
AU5910896A (en) Novel water-soluble fluoroethylcamptothecin derivative and process for production thereof
EP0739905A4 (en) POLYMERIZATION CATALYST AND METHOD FOR PRODUCING POLYSTYRENE WITH THIS CATALYST
WO2007020642A2 (en) A method of preparing functionalized molecularly imprinted polymers using labile linking
EP0601318A3 (de) Verfahren zur Herstellung von Konjugaten aus einem spezifischen Bindungspartner und einem kohlenhydrathaltigen Protein.
FR2828883B1 (fr) Produit d'addition-esterification d'acide sur ester glycidylique, procede de preparation d'un tel produit, et composition durcissable contenant un tel produit
US5196536A (en) 2-Fluoro-1-methylpyridinium salt activated diols and polyols as cross-linkers
US5130436A (en) 2-fluoro-1-methylpyridinium salt activated diols and polyols as cross-linkers
EP0569086A3 (en) Method and kit for attaching compounds to carboxylated substrates using uronium salt